WO1998015635A3 - Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine - Google Patents
Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine Download PDFInfo
- Publication number
- WO1998015635A3 WO1998015635A3 PCT/CA1997/000729 CA9700729W WO9815635A3 WO 1998015635 A3 WO1998015635 A3 WO 1998015635A3 CA 9700729 W CA9700729 W CA 9700729W WO 9815635 A3 WO9815635 A3 WO 9815635A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cytokine
- nucleic acid
- virus
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44485/97A AU4448597A (en) | 1996-10-04 | 1997-10-03 | Treatment of cancer using a recombinant poxvirus containing nucleic acid sequence encoding a cytokine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2753096P | 1996-10-04 | 1996-10-04 | |
US60/027,530 | 1996-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998015635A2 WO1998015635A2 (en) | 1998-04-16 |
WO1998015635A3 true WO1998015635A3 (en) | 1998-07-09 |
Family
ID=21838268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1997/000729 WO1998015635A2 (en) | 1996-10-04 | 1997-10-03 | Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4448597A (en) |
WO (1) | WO1998015635A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69926742T2 (en) | 1998-04-14 | 2006-06-14 | Sugen Inc | STE20-RELATED PROTEIN KINASES |
CA2412050C (en) * | 2000-06-15 | 2011-03-22 | Jeffrey Schlom | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016716A1 (en) * | 1993-01-21 | 1994-08-04 | Virogenetics Corporation | Recombinant virus immunotherapy |
-
1997
- 1997-10-03 AU AU44485/97A patent/AU4448597A/en not_active Abandoned
- 1997-10-03 WO PCT/CA1997/000729 patent/WO1998015635A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016716A1 (en) * | 1993-01-21 | 1994-08-04 | Virogenetics Corporation | Recombinant virus immunotherapy |
Non-Patent Citations (12)
Title |
---|
90TH ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION, 23 April 1995 (1995-04-23) - 28 April 1995 (1995-04-28), LAS VEGAS, USA, XP002062562 * |
91ST AANUAL MEETING OF THE AMERICAN UROLOGY ASSOCIATION, no. 5, 4 May 1996 (1996-05-04) - 9 May 1996 (1996-05-09), ORLANDO, FLORIDA, USA, XP002062560 * |
91ST ANNUAL MEETING OF THE AMERICAN UROLOGY ASSOCIATION, 4 May 1996 (1996-05-04) - 9 May 1996 (1996-05-09), ORLANDO , FLORIDA,USA, XP002062561 * |
BRAMSON J: "IMMUNOTHERAPY OF MURINE BREAST CANCER USING AN ADENOVIRUS VECTOR EXPRESSING INTERLEUKIN-12", PROCEEDINGS OF THE 87TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, APR. 20 - 24, 1996, no. MEETING 87, 1 March 1996 (1996-03-01), AMERICAN ASSOCIATION FOR CANCER RESEARCH, pages 341, XP000574942 * |
G.S. RAO ET AL: "Canary pox (ALVAC) virus mediated cytokine gene therapy induces tumor specific immunity against mouse bladder tumor", JOURNAL OF UROLOGY, vol. 155, no. 5suppl., May 1996 (1996-05-01), pages 570A * |
I. PUISIEUX ET AL: "Curative and protective effects against murine tumors by iL-12 gene therapy using a canary pox virus vector", CANCER GENE THERAPY, vol. 4, no. 6 conf. suppl., November 1997 (1997-11-01), pages S53 * |
M. KAWAKITA ET AL: "Canary pox (ALVAC) virus-mediated cytokinegene therapy induces tumor specific and non-specific immunity against mouse prostate tumor", JOURNAL OF UROLOGY, vol. 155, no. 5 suppl., May 1996 (1996-05-01), pages 516A * |
M. KAWAKITA ET AL: "Effect of canary-pox (ALVAC) virus-mediated cytokine gene expression on prostate tumor growth", JOURNAL OF UROLOGY, vol. 153, no. 4, April 1995 (1995-04-01), pages 469A * |
M. KAWAKITA ET AL: "Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 89, no. 6, 19 March 1997 (1997-03-19), pages 428 - 436, XP002062563 * |
PAOLETTI E ET AL: "IMMUNOTHERAPEUTIC STRATEGIES FOR CANCER USING POXVIRUS VECTORS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 690, 12 August 1993 (1993-08-12), pages 292 - 300, XP002042659 * |
SEDLACEK H H: "VACCINATION FOR TREATMENT OF TUMORS: A CRITICAL COMMENT", CRITICAL REVIEWS IN ONCOGENESIS, vol. 5, no. 6, 1994, pages 555 - 587, XP000198151 * |
SIXTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER, 2 November 1997 (1997-11-02) - 22 November 1997 (1997-11-22), SAN DIEGO,CALIFORNIA,USA, XP002062564 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998015635A2 (en) | 1998-04-16 |
AU4448597A (en) | 1998-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000055345A3 (en) | Therapy of cancer by insect cells containing recombinant baculovirus encoding genes | |
EP0168214A3 (en) | Tumor necrosis factor, methods for its preparation, compositions containing it, dna encoding it and assay method using such dna | |
MY101852A (en) | Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna. | |
DK0835133T3 (en) | Recombinant smallpox virus rabies and combination preparations and their uses | |
IL144371A0 (en) | Her-2/neu fusion proteins | |
EP1005376A4 (en) | Methods and compositions for use in gene therapy for treatment of hemophilia | |
WO1995030761A3 (en) | Methods of in vivo gene delivery | |
WO2002012341A3 (en) | Her-2/neu fusion proteins | |
WO1999047674A3 (en) | Compounds and methods for therapy and diagnosis of lung cancer | |
WO2000061612A3 (en) | Compounds and methods for therapy and diagnosis of lung cancer | |
WO2000012127A3 (en) | Dna cancer vaccine and methods for its use | |
DE69233186D1 (en) | KARCINOEMBRYONAL ANTIGENT EXPECTING RECOMBINANT VIRUSES AND METHODS OF USE | |
EP0961831A4 (en) | Human endokine alpha | |
WO2003039458A3 (en) | TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α | |
CA2234263A1 (en) | Pharmaceutical composition for treating papillomavirus tumours and infection | |
GB9922361D0 (en) | Generating an immune response to an antigen | |
WO1999047678A3 (en) | Interferon alpha plasmids and delivery systems, and methods of making and using the same | |
WO1998015635A3 (en) | Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine | |
NZ516237A (en) | Meth1 and meth2 polynucleotides and polypeptides | |
WO2002094859A3 (en) | Mage-a1 peptides for treating or preventing cancer | |
EP0811687A3 (en) | Polypeptides having l-asparaginase activity | |
EP1731611A3 (en) | Eimeria hydrophilic polypeptides as vaccines | |
WO2001004318A3 (en) | Myxoma virus genes for immune modulation | |
WO1998024912A3 (en) | Recombinant plague vaccine | |
RU2005125608A (en) | VACCINE BASED ON MUCIN MUC-1 EPITHELIAL CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998516022 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |